PATENT CLAIM ANALYSIS

Application Number: 15983249
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "007200"]

Abstract:
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Claim (Index 12):
The method of  claim 7 , wherein the GLP-1 analog is exenatide or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.15625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14071976', '12258340', '13257284', '13511771', '15142227']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7222356275746006
- 35 USC 102 Novelty (BERT): 0.6074904235544605
- Combined Prediction Score: 0.7107611071725867
- Mean Citation Score: 333.588256
- Max Citation Score: 547.05524
- Similarity Product: 456.02553312772767

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test